Inventiva announces participation at several conferences in January and February 2022
January 20, 2022 16:00 ET | INVENTIVA
Daix (France), Long Island City (New York, United States), January 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Inventiva annonce sa participation à plusieurs conférences investisseurs en janvier et février 2022
January 20, 2022 16:00 ET | INVENTIVA
Daix (France), Long Island City (New York, United States), le 20 janvier 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
January 04, 2022 16:05 ET | Angion Biomedica Corp.
-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE,...
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
December 16, 2021 16:00 ET | INVENTIVA
Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule...
Inventiva annonce sa participation à la « 40th Annual J.P. Morgan Healthcare Conference »
December 16, 2021 16:00 ET | INVENTIVA
Daix (France), Long Island City (New York), le 16 décembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules...
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
December 06, 2021 16:00 ET | INVENTIVA
Trial conducted in 217 patients to evaluate the potential effect of lanifibranor on the QT/QTc interval in healthy subjects and to support lanifibranor New Drug Application (NDA) package in NASH ...
Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranor
December 06, 2021 16:00 ET | INVENTIVA
Etude  conduite chez 217 volontaires sains afin d’évaluer l’effet de lanifibranor sur l’intervalle QT/QTc et de soutenir la demande d’enregistrement d’un nouveau médicament (New Drug Application...
PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD - The Liver Meeting Digital Experience™ (TLMdX) 2021
November 12, 2021 08:00 ET | PHARMANEST
PRINCETON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PharmaNest is a digital pathology and artificial intelligence company that is focused on the development and validation of novel standards for...
Inventiva reports 2021 Third Quarter Financial Information
November 10, 2021 16:00 ET | INVENTIVA
Cash and cash equivalents at €105.7m as of September 30, 2021Revenues of €0.2m for the first nine months of 2021 Daix (France), Long Island City (New York, United States), November 10, 2021 –...
Inventiva publie ses informations financières du 3ème trimestre 2021
November 10, 2021 16:00 ET | INVENTIVA
Trésorerie et équivalents de trésorerie à 105,7 M€ au 30 septembre 2021 Chiffre d’affaires de 0,2 M€ sur les neuf premiers mois de 2021 Daix (France), Long Island City (New York, United States),...